long intergenic non-protein coding RNA 2692Genealiases: C9orf141 · PRR31
Q-omics provides the consensus-scored LINC02692 profile across patient tissues and cancer cell-line models. LINC02692 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LINC02692 is differentially expressed in 5, with the highest sampling consensus in PRAD. Additionally, LINC02692 RNA expression shows 6,712 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, PRAD, and STAD as cancer lineages where LINC02692 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02692 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02692 survival associations across molecular data types. LINC02692 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02692 RNA expression–survival associations across cancer types. High LINC02692 expression shows unfavorable associations in ACC, UVM, OV, KIRC and BRCA, but favorable associations in ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LINC02692 RNA expression.
This table summarizes LINC02692 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02692. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02692 shows lower tumor expression in PRAD, LUSC, THCA and KICH and higher tumor expression in STAD. The PRAD box plot shows higher LINC02692 RNA expression in normal versus tumor tissue (log2 FC = −0.374, t-test p = .004).
This table shows molecular features associated with LINC02692 in patient tissues and cancer cell lines. In patient samples, LINC02692 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
